Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease

NCT03157037 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER_GOV

Sponsor class

Conditions

Anti-Glomerular Basement Membrane Antibody Disease

Interventions

BIOLOGICAL: Imlifidase

Sponsor

Mårten Segelmark

Collaborators

[object Object]